Instrument Inactif

Communiqués Transcept Pharmaceuticals Inc Nasdaq

Actions

US89354M1062

Produits pharmaceutiques

Cours en clôture Nasdaq Autres places de cotation
- ^USD	-

18/03	Paratek Pharmaceuticals, Inc. acquiert Radius Health, Inc. auprès de B-Flexion Advisors (UK) LLP, Gurnet Point Capital Limited, OrbiMed Advisors LLC, Patient Square Capital, LP et Webster Equity Partners, L.P.	CI
24/02	Paratek Pharmaceuticals annonce des résultats positifs pour les études d'efficacité thérapeutique de NUZYRA contre l'anthrax inhalé, déclenchant un nouvel approvisionnement dans le cadre du contrat Project Bioshield avec BARDA	CI

Communiqués

05/10/23	Healthcare & Life Sciences Private Equity Deal Tracker: Gurnet Point And Novo Holdings Acquire Paratek Pharmaceuticals	AQ
05/10/23	Paratek Pharmaceuticals to Present NUZYRA Data at IDWeek 2023	AQ
21/09/23	Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.	AQ
18/09/23	Paratek Pharmaceuticals Announces Stockholder Approval of Acquisition by Gurnet Point Capital and Novo Holdings A/S	AQ
12/09/23	Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings A/S	AQ
07/09/23	Leading Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings	GL
09/08/23	Investor Alert: Abbott Cooper PLLC Announces Investigation into Paratek Pharmaceuticals, Inc.; Urges Paratek Stockholders to Contact Abbott Cooper Regarding Their Legal Rights	BU
03/08/23	Paratek: Q2 Earnings Snapshot	AQ
03/08/23	Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue of $40.0 Million	AQ
02/08/23	Paratek Pharmaceuticals Files Definitive Proxy Statement and Letter to Stockholders in Connection with Acquisition by Gurnet Point Capital and Novo Holdings	AQ
11/07/23	NexPoint Sends Demand Letter for Books and Records to Paratek Pharmaceuticals in Connection with Proposed Acquisition by Gurnet Point Capital	PR
10/07/23	Paratek Pharmaceuticals Announces Modification of BARDA Contract to Advance the Development of NUZYRA® (omadacycline) for Post-Exposure Prophylaxis (PEP) and Treatment of Pulmonary Anthrax	AQ
27/06/23	Paratek Pharmaceuticals Acknowledges Receipt of NexPoint Letter	AQ
27/06/23	European Medicines Agency COMP Recommends Positive Opinion on Orphan Medicinal Product Designation for NUZYRA® (omadacycline) for Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease	AQ
20/06/23	PRTK Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Paratek Pharmaceuticals to Gurnet Point Capital and Novo Holdings	AQ
12/06/23	Paratek Pharmaceuticals Presenting New Data from NUZYRA® (omadacycline) and Investigator-Initiated Research Programs at ASM Microbe 2023	AQ
07/06/23	PARATEK PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
06/06/23	Paratek Pharmaceuticals to be Acquired by Gurnet Point Capital and Novo Holdings	AQ
09/05/23	Paratek: Q1 Earnings Snapshot	AQ
09/05/23	Paratek Pharmaceuticals Announces First Quarter 2023 Revenue of $31.2 Million	AQ
01/05/23	Paratek Pharmaceuticals to Report Financial Results for First Quarter 2023 on May 9	AQ
10/04/23	Paratek Pharmaceuticals Presenting New Data from NUZYRA® (omadacycline) and Investigator-Initiated Research Programs at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) 2023	AQ
16/03/23	Paratek Pharmaceuticals : Corporate Presentation - Spring 2023	PU
16/03/23	PARATEK PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	AQ
16/03/23	Paratek Pharmaceuticals Announces Full-Year 2022 Revenue of $160.3 Million	AQ